
MSD is trialling an implant that prevents patients from contracting HIV, The Guardian has said. The US firm has tested …

Massachusetts-based biotech Disarm Therapeutics has hired Dr Alvin Shih as their new President and CEO. The Cambridge, Mass.-based firm has …

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …

Drug resistant malaria parasites are spreading rapidly in South East Asia, according to researchers from Thailand and the United Kingdom. …

The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the …

Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat …

Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, …

Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, …

Celgene has revealed the US approval of Otezla (apremilast), confirming that the FDA awarded marketing authorisation for the treatment of …

The world needs cheap generic drugs and Indian manufacturers offer a steady supply. However the quality of generics has been …

The Department of Health and Social Care paid £9.2 billion to private providers in the year prior to 31 March …

Federal prosecutors in Cincinnati have filed criminal charges against opioid distributor Miami-Luken, and four others, over the role they played …

A report from the Home Office of the UK Government has revealed that the prevalence of animal testing in the …

On 12 July news broke that Novartis, Amgen and Banner’s Alzheimer’s Institute were discontinuing a trial into investigational compound CNP520 …

Novartis has revealed that its disease modifying drug Gilenya (fingolimod) has secured approval in China for the treatment of relapsing …

The Democratic Republic of Congo (DRC) has said it will stick with Merck’s rVSV-ZEBOV ebola vaccine, as it ruled out …

The Royal Pharmaceutical Society (RPS) in Scotland has raised concerns that the Government’s contingency plans do not eliminate the risks …

Gilead has said that Dr John McHutchison is stepping down after nine years at the firm. Gilead’s Chief Scientific Officer …

The release of Women Count 2019, an annual report funded by The Pipeline, has revealed that “little to no progress” …